SNSS:NASDAQ

Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
SNSS:NASDAQ

Expert Comments:

Maxim Jacobs, Edison Investment Research (6/23/16)
"Sunesis Pharmaceuticals Inc. is a pharmaceutical company developing small molecule oncology drugs. Its lead program is Qinprezo [for] relapsed/refractory acute myeloid leukemia. . .the company is also advancing its clinical asset, SNS-062, a novel, non-covalent, oral BTK inhibitor that may work in Imbruvica-relapsed and refractory patients. . .Sunesis is an oncology company with a late-stage asset, potentially near European approval, as well as preclinical assets utilizing promising targets, making it an attractive partner."

Maxim Jacobs, Edison Investment Research (6/22/16)
"Sunesis Pharmaceuticals Inc. reported results from an Phase 1b/2 study sponsored by MD Anderson. . .detailing the effect of a combination of Qinprezo and Dacogen for the front-line treatment of patients with acute myeloid leukemia [and] myelodysplastic syndrome. . .the 63-person open-label trial demonstrated a median overall survival of 16.1 months at the 70mg/m2 Qinprezo dose, over twice that of either of the drugs alone. . .we are increasing our valuation. . .this increase reflects the encouraging results from the Qinprezo/Dacogen combination study and a potential new path to approval in frontline AML."

Hartaj Singh, BTIG Research (5/10/16)
"Sunesis Pharmaceuticals Inc. provided a deeper dive into the SNS-062 program where the first subject was dosed in 1Q16 and where preclinical data from AACR 2015 leads us to believe that this molecule could be a blockbuster in patients with acquired resistance mutations to BTK inhibitors like ibrutinib. We stay bullish. . .we believe that by 2020E, there will be ~150-200K patients treated by ibrutinib. Assuming a 10% to 15% resistance-mutation rate, there should be ~17K to 28K such patients by 2020E, potentially a multibillion market opportunity for SNS-062. We are very intrigued."

Maxim Jacobs, Edison Investment Research (4/21/16)
"Significant potential remains in Europe where Sunesis Pharmaceuticals Inc.'s Qinprezo has data comparable to those used in other related approvals. The company is also advancing SNS-062, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients."

Hartaj Singh, BTIG Research (4/18/16)
"Near-term focus remains on European Union (EU) feedback on Sunesis Pharmaceuticals Inc.'s (Buy, $2.50 price target) vosaroxin application; other catalysts are progression of a U.S. filing strategy for vosaroxin and more color on the BTK inhibitor SNS-062 and the EU dose ranging trials. We stay bullish."

"Sunesis Pharmaceuticals Inc.'s Phase 3 VALOR trial of vosaroxin (Qinprezo) with cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML) did not achieve the primary endpoint of overall survival. But the company looked at the data, and found that there was actually a significant survival benefit in patients who were 60 years of age or older, and especially in patients who achieved a complete response. Notably, Sunesis found that the addition of vosaroxin to cytarabine more than doubled the complete response rate. So Sunesis is going after registration in the European Union (EU). This is not unlike what Eisai Inc. did with its epigenetic inhibitor Dacogen (decitabine). . .we will watch and see what happens. Meanwhile, Sunesis has an early-stage pipeline to work on, but those drugs are several years out." read more >

More Expert Comments

Experts Following This Company

Matthew Andrews, Equity Senior Analyst – Wells Fargo Securities
Mara Goldstein, Senior Analyst – Cantor Fitzgerald
Maxim Jacobs – Edison Investment Research
Alan Leong, CEO – BioWatch News
David Nierengarten, Research Analyst – Wedbush
Hartaj Singh, Biotechnology Analyst – BTIG Research
George Zavoico, Senior Equity Analyst – JonesTrading

The information provided above is from analysts, newsletters, the company and other contributors.

Sunesis Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Totality of VALOR data shows compelling risk-benefit trade-off in disease with significant unmet need
 
Relapsed/refractory AML is a significant commercial opportunity with no approved agents
 
Company's kinase inhibitor pipeline is poised to progress to the clinic in 2015 and 2016